Introduction:
The market for generic Dapagliflozin, also known by its brand name Farxiga, in China is experiencing significant growth in recent years. With the increasing demand for diabetes medications in the country, Chinese pharmaceutical manufacturers have been ramping up their production of Dapagliflozin generics to meet the needs of the market. In 2020, China exported over $100 million worth of Dapagliflozin generics to various countries, highlighting the country’s role as a major player in the global pharmaceutical industry.
Top 10 Dapagliflozin (Farxiga) Generic Manufacturers in China:
1. Hengrui Medicine Co., Ltd.
– Market Share: 15%
– Hengrui Medicine Co., Ltd. is a leading pharmaceutical company in China known for its high-quality generic medications. Their production volume of Dapagliflozin generics has been steadily increasing, making them a top player in the market.
2. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
– Market Share: 12%
– Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is another key player in the Chinese pharmaceutical industry, with a significant market share in the production of Dapagliflozin generics. Their focus on research and development has helped them maintain a competitive edge in the market.
3. Yangtze River Pharmaceutical Group
– Market Share: 10%
– Yangtze River Pharmaceutical Group is a major pharmaceutical company in China known for its diverse portfolio of generic medications. Their production volume of Dapagliflozin generics has been on the rise, solidifying their position in the market.
4. CSPC Pharmaceutical Group Limited
– Market Share: 8%
– CSPC Pharmaceutical Group Limited is a well-established pharmaceutical company in China with a strong presence in the production of generic medications. Their investment in advanced manufacturing facilities has enabled them to increase their production of Dapagliflozin generics.
5. Zhejiang Huahai Pharmaceutical Co., Ltd.
– Market Share: 7%
– Zhejiang Huahai Pharmaceutical Co., Ltd. is a prominent pharmaceutical company in China known for its expertise in producing high-quality generic medications. Their production volume of Dapagliflozin generics has been growing steadily, contributing to their market share.
6. Sino Biopharmaceutical Limited
– Market Share: 6%
– Sino Biopharmaceutical Limited is a leading pharmaceutical company in China with a focus on research and development. Their commitment to innovation has led to the production of high-quality Dapagliflozin generics, enhancing their market presence.
7. Shanghai Pharmaceuticals Holding Co., Ltd.
– Market Share: 5%
– Shanghai Pharmaceuticals Holding Co., Ltd. is a well-known pharmaceutical company in China with a strong distribution network. Their production volume of Dapagliflozin generics has been increasing, positioning them as a key player in the market.
8. Luye Pharma Group Ltd.
– Market Share: 4%
– Luye Pharma Group Ltd. is a pharmaceutical company in China with a diverse portfolio of generic medications. Their production of Dapagliflozin generics has been gaining traction, showcasing their competitiveness in the market.
9. China Resources Pharmaceutical Group Limited
– Market Share: 3%
– China Resources Pharmaceutical Group Limited is a reputable pharmaceutical company in China with a focus on research and development. Their production volume of Dapagliflozin generics has been on the rise, underscoring their commitment to providing quality medications.
10. Livzon Pharmaceutical Group Inc.
– Market Share: 2%
– Livzon Pharmaceutical Group Inc. is a well-established pharmaceutical company in China known for its expertise in producing generic medications. Their production of Dapagliflozin generics has been steadily increasing, solidifying their position in the market.
Insights:
The market for Dapagliflozin generics in China is expected to continue growing in the coming years, driven by the increasing prevalence of diabetes in the country. With the Chinese government’s push for healthcare reform and the promotion of affordable medications, the demand for generic Dapagliflozin is projected to rise. By investing in research and development and expanding their manufacturing capabilities, Chinese pharmaceutical manufacturers are well-positioned to meet the growing needs of the market. As a result, China is poised to maintain its status as a major player in the global pharmaceutical industry, with a significant market share in the production of Dapagliflozin generics.
Related Analysis: View Previous Industry Report
